- Home
- SEZL vs RCUS Comparison
SEZL vs RCUS Comparison
Compare SEZL & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEZL
- RCUS
- Stock Information
- Founded
- SEZL 2016
- RCUS 2015
- Country
- SEZL United States
- RCUS United States
- Employees
- SEZL N/A
- RCUS N/A
- Industry
- SEZL Diversified Financial Services
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- SEZL Finance
- RCUS Health Care
- Exchange
- SEZL Nasdaq
- RCUS Nasdaq
- Market Cap
- SEZL 1.3B
- RCUS 1.2B
- IPO Year
- SEZL N/A
- RCUS 2018
- Fundamental
- Price
- SEZL $251.00
- RCUS $8.40
- Analyst Decision
- SEZL Strong Buy
- RCUS Strong Buy
- Analyst Count
- SEZL 2
- RCUS 11
- Target Price
- SEZL $368.50
- RCUS $31.78
- AVG Volume (30 Days)
- SEZL 178.0K
- RCUS 1.0M
- Earning Date
- SEZL 05-07-2025
- RCUS 05-07-2025
- Dividend Yield
- SEZL N/A
- RCUS N/A
- EPS Growth
- SEZL 950.40
- RCUS N/A
- EPS
- SEZL 13.13
- RCUS N/A
- Revenue
- SEZL $271,127,890.00
- RCUS $258,000,000.00
- Revenue This Year
- SEZL $33.01
- RCUS N/A
- Revenue Next Year
- SEZL $16.24
- RCUS $28.07
- P/E Ratio
- SEZL $19.12
- RCUS N/A
- Revenue Growth
- SEZL 70.14
- RCUS 120.51
- 52 Week Low
- SEZL $40.39
- RCUS $8.31
- 52 Week High
- SEZL $477.52
- RCUS $19.11
- Technical
- Relative Strength Index (RSI)
- SEZL 50.91
- RCUS 29.68
- Support Level
- SEZL $223.28
- RCUS $8.83
- Resistance Level
- SEZL $243.11
- RCUS $9.19
- Average True Range (ATR)
- SEZL 18.75
- RCUS 0.49
- MACD
- SEZL 1.06
- RCUS 0.04
- Stochastic Oscillator
- SEZL 79.58
- RCUS 4.70
About SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.